Strides Vivimed JV receives approval for Albendazole Tablets
Deepthi | Myequity news | Date : 11-12-2018 10:25:00 IST
Strides Vivimed Pte. Ltd, Singapore has received approval for Albendazole Tablets USP 200 mg from the United States Food & Drug Administration (US FDA). This is the second generic approval by US FDA for Albendazole Tablets.
Albendazole Tablets is a generic version of Albenza Tablets® of Amneal Pharmaceuticals, Inc. According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately US$ 100 Mn.
About Albendazole Tablets
Albendazole is an anthelmintic medication used to treat certain infections caused by tapeworm. Albendazole prevents newly hatched insect larvae (worms) from growing or multiplying in the body.
Strides is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has a global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 Regulated market facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries.